Patient Profiles
Meet Max‡ — a patient with ALL
30 years of age1
Initial presentation1
- Max was undergoing ONCASPAR® treatment for ALL
- Unfortunately, he developed grade 1 hypersensitivity to ONCASPAR® during the course of treatment.
Treatment plan1
- Max’s doctor reduced the ONCASPAR® infusion rate by 50%, and monitored him for an hour after infusion
- Max’s doctor also initiated a therapeutic drug monitoring plan to monitor his allergic reactions
Max was able to remain on and complete treatment for ALL1
Consider ONCASPAR® as part of the chemotherapy regimen for your patients like Max
aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.
* Clinical significance has not been established.
† Comparative clinical significance has not been established.
‡ Fictitious cases. May not be representative of all patients.
§ Native E. coli L-asparaginase is not available in Canada.
References:
- ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
- ONCASPAR_CPID Redacted.
- ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
- RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
- Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
